Mizuho lowered the firm’s price target on Amylyx Pharmaceuticals to $46 from $48 and keeps a Buy rating on the shares following news last week of a second negative opinion by Europe’s CHMP on potential approval of Relyvri. While a final decision on European approval has yet to come, the firm pushed potential first EU-related product sales from 2024 to 2027. It remains bullish on Relyvrio’s longer-term prospects.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AMLX:
- Amylyx announces CHMP opinion on AMX0035 MAA
- Amylyx publishes ITT survival analysis of Centaur to historical control
- Mizuho expects news this week from Europe on Amylyx’s Relyvrio
- Amylyx provides update on Compassionate Access for AMX0035 in France
- Amylyx investor share sale not due to disagreement, says Mizuho